Keymed Biosciences Announces 2025 Annual Results and Business Updates
BEIJING, March 26, 2026 /PRNewswire/ -- Keymed Biosciences (HKEX: 02162) announced its 2025 annual results. The year marked the company's 10th anniversary and a pivotal year in its transition from R&D to commercialization. Revenue Leaps Forward,...
Keymed Biosciences Announces the Latest Clinical Trial Results of CM336 Published in the New England Journal of Medicine
CHENGDU, China, June 12, 2025 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) today announced that Prof. Jun Shi's research team from the Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences (Institute of...
